Cosmos Health distributes branded pharmaceuticals across Europe and sells its own supplement brands, Sky Premium Life, Mediterranation and Oliv18.
The company just posted record first-half 2026 revenue of $36.9 million, signed an exclusive Saudi Arabia distribution deal, and set a U.S. revenue target for Oliv18. Here's a quick look at the company, the hero stats, and the catalysts putting it on our radar.
Cosmos Health distributes branded pharmaceuticals across the EU through its Greek subsidiary Sky Pharm and sells its own supplement brands — Sky Premium Life, Mediterranation and Oliv18.
The company reported record Q2 2026 revenue of $19.0 million, up 28.8% year over year, record first-half revenue of $36.9 million, adjusted gross profit up 58%, total liabilities down 13%, and stockholders' equity up 12% — while running a $5 million share repurchase program.
The August 20, 2026 exclusive distribution agreement with Innova Healthcare opening the Saudi Arabian market to Sky Premium Life, beginning with an initial 126,000-unit purchase order and more than 5 million units expected over an initial five-year term.
What stands out is the combination of scale and momentum at a micro-cap valuation: a business already turning over roughly $75 million on an adjusted annualized run-rate basis, with margin expansion, a shrinking liability base, and two brand-led growth channels opening at the same time.
Cosmos Health Inc. (NASDAQ: COSM) is a Nevada-incorporated healthcare group with its principal operations in Thessaloniki, Greece, combining pharmaceutical wholesale distribution with a growing portfolio of proprietary nutraceutical brands.
The company distributes roughly 500 branded pharmaceutical products across EU markets through its GDP-certified subsidiary Sky Pharm SA, and develops and sells its own supplement lines — Sky Premium Life, Mediterranation and the newer olive-derived Oliv18 — plus branded generics and over-the-counter products.
Customers include pharmaceutical wholesalers, distributors and retailers across the European Union, together with a growing set of international distribution partners and retail channels for the company's own supplement brands.
Revenue comes primarily from wholesale pharmaceutical distribution margins, with higher-margin growth intended to come from proprietary nutraceutical brands sold through distribution agreements and retail channels.
Corporate offices in Chicago, Illinois, with core operating, warehousing and distribution activity in Thessaloniki, Greece, and expanding international distribution reach including the Middle East and the United States.
Cosmos Health is a revenue-generating micro-cap that reported record FY2025 revenue of $65.3 million and record first-half 2026 revenue of $36.9 million, while remaining unprofitable. Its most recent quarterly filing includes going-concern language, which investors should read in full.
The points below draw on the company's public disclosures, its recent operational updates, and TopStocks commentary. We distinguish between confirmed facts, company statements, and our own editorial framing.
Cosmos Health reported all-time record FY2025 revenue of $65.3 million, up 20% year over year, with gross profit up 83% to $7.9 million and gross margin expanding 418 basis points. That growth carried into 2026: Q2 revenue of $19.0 million was up 28.8% from $14.75 million, and first-half revenue of $36.9 million was up 29.7% from $28.46 million. On an adjusted basis, management pointed to a Q2 annualized run-rate above $75 million.
The core business is Sky Pharm SA, a GDP-certified wholesaler regulated by the Greek EOF that sources roughly 500 branded pharmaceutical products and distributes them across European Union markets. It is an asset-light trading model that has scaled revenue to tens of millions of dollars with a small headcount.
Sky Premium Life, Mediterranation and Oliv18 are the company's proprietary lines, and they carry materially higher margins than wholesale distribution. Management reported adjusted gross profit up 58% in Q2 2026 — the kind of mix shift the brand strategy is designed to produce.
On August 20, 2026 Cosmos Health announced an exclusive distribution agreement with Innova Healthcare covering Saudi Arabia for Sky Premium Life. The agreement began with an initial purchase order of 126,000 units, and the company said more than 5 million units are expected over an initial five-year term. Innova is backed by Alkhabeer Capital and other regional investors. Purchase expectations over a multi-year term are not guaranteed orders.
On August 24, 2026 the company projected that Oliv18, its olive-derived cardiovascular-health and antioxidant supplement, could generate more than $6 million in annual U.S. revenue and roughly $4.3 million in gross profit within 12 to 18 months. These are management projections, not results, and may not be achieved.
Alongside Q2 2026 results the company reported total liabilities reduced 13% and stockholders' equity up 12%, and disclosed an ongoing $5 million open-market share repurchase program. Cash stood at $3.5 million at the end of FY2025, up roughly tenfold year over year. The Q2 filing nonetheless contains going-concern language, and an active $200 million shelf registration means future capital raises could be dilutive.
The following points are drawn from Cosmos Health's own FY2025 and Q2 2026 results releases, reproduced here as the company reported them.
All-time record FY2025 revenue of $65.3 million, up 20% year over year.
Q2 2026 revenue of $19.0 million, up 28.8%, and H1 2026 revenue of $36.9 million, up 29.7%.
Adjusted Q2 2026 revenue implies an annualized run-rate above $75 million.
Adjusted Q2 2026 gross profit up 58%; FY2025 gross margin expanded 418 basis points.
Total liabilities reduced 13% and stockholders' equity up 12% as reported with Q2 2026 results.
A $5 million open-market share repurchase program was underway as of the Q2 2026 report.
Exclusive Saudi Arabia distribution agreement plus a projected U.S. launch for Oliv18.
Adjusted figures are non-GAAP measures defined by management and are not a substitute for results reported under GAAP. Cosmos Health remains unprofitable, and its most recent quarterly filing includes going-concern language. Revenue growth does not imply profitability. Investors should confirm all figures against the company's filings with the SEC before making any investment decision.
Cosmos Health pairs a European pharmaceutical wholesale business that already turns over tens of millions of dollars a year with a set of proprietary consumer health brands carrying much higher margins — and both sides grew in the first half of 2026.
The company's GDP-certified pharmaceutical wholesaler, regulated by the Greek EOF, sourcing roughly 500 branded pharmaceutical products and distributing them across European Union markets. It is the asset-light trading operation behind the majority of reported revenue.
Branded pharmaceutical products sourced and distributed across EU markets.
The company's flagship nutraceutical line and the subject of the August 20, 2026 exclusive distribution agreement with Innova Healthcare for Saudi Arabia, which opened with an initial purchase order of 126,000 units.
Company expectation over an initial five-year term in Saudi Arabia. Expectations are not committed orders.
A proprietary olive-derived supplement targeting the U.S. cardiovascular health and antioxidant categories. On August 24, 2026 management projected it could generate more than $6 million of annual revenue and roughly $4.3 million of gross profit within 12 to 18 months.
Management projection within 12–18 months at approximately 72% gross margin. Projections are not results.
A Mediterranean-positioned consumer wellness line rounding out the proprietary portfolio alongside the company's branded generics and over-the-counter products, all of which carry higher margins than third-party wholesale distribution.
Own brands are the driver behind the 58% adjusted gross profit increase in Q2 2026.
Distribution agreements, unit expectations and revenue projections described above are forward-looking statements made by the company and are not guarantees of future orders, revenue or profitability. Actual results may differ materially. Read the company's SEC filings.
Join free TopStocks alerts for daily stock picks, market news, and the next featured company on our radar.
The company projected that its proprietary Oliv18 supplement could add more than $6 million in incremental annual U.S. revenue within 12 to 18 months across the cardiovascular health and antioxidant categories, implying roughly $4.3 million of gross profit at approximately 72% gross margin.
Cosmos Health secured an exclusive agreement to distribute Sky Premium Life products in Saudi Arabia through Innova Healthcare, starting with an initial purchase order of 126,000 units, with more than 5 million units expected over an initial five-year term. Innova is backed by Alkhabeer Capital and other regional investors.
Q2 2026 revenue of $18.99 million was up 28.8% from $14.75 million a year earlier, and first-half revenue of $36.91 million was up 29.7% from $28.46 million. The company also reported adjusted Q2 gross profit up 58%, total liabilities reduced 13%, stockholders' equity up 12%, and an ongoing $5 million share repurchase program.
Ahead of its formal results the company reported preliminary Q2 2026 revenue of approximately $19.4 million, up roughly 31.5% year over year, and preliminary first-half revenue of approximately $37.3 million, while confirming it continued open-market share repurchases.
FY2025 revenue reached an all-time record $65.3 million, up 20% year over year. Gross profit rose 83% to $7.9 million, gross margin expanded 418 basis points, adjusted EPS improved 82%, and the cash position increased roughly tenfold to $3.5 million.
Upcoming events retail investors are monitoring for COSM. None of these outcomes are guaranteed.
Shipment and sell-through of the initial 126,000-unit Sky Premium Life purchase order, followed by the ramp toward the more than 5 million units the company expects over an initial five-year term.
Retail and channel rollout of Oliv18 in the U.S. cardiovascular health and antioxidant categories, against management's projection of more than $6 million of annual revenue and roughly $4.3 million of gross profit.
Third-quarter results will show whether the revenue and margin trend continued. Separately, investors should track Nasdaq's $1.00 minimum bid price requirement and the company's active $200 million shelf registration.
Potential catalysts may be delayed, changed, unsuccessful, or already reflected in the stock's market price.
A diversified healthcare micro-cap with record revenue, a new Saudi distribution channel, and a proprietary U.S. launch pipeline — Cosmos Health Inc. has moved quickly on all three fronts.
None of that guarantees continued growth or profitability, and the company's own filings deserve a careful read. But the execution so far is real, and COSM stays firmly on our radar.
This is sponsored editorial content, not investment advice. See the full disclosure below before making any investment decision.
Live quote.
Live quote.
All-time record full-year 2025 revenue, up 20% year over year, as reported by the company.
Second-quarter 2026 revenue of $18.99 million, up 28.8% from $14.75 million in the prior-year quarter.
First-half 2026 revenue of $36.91 million, up 29.7% from $28.46 million a year earlier.
Full-year 2025 gross profit, up 83% year over year, with gross margin expanding 418 basis points.
Financial figures should be verified against the company's latest SEC filings. Historical performance does not guarantee future results.
Look up Cosmos Health Inc. (NASDAQ: COSM) on your preferred trading platform to review real-time quotes, charts, and filings.
Brokerage names and logos are trademarks of their respective owners. TopStocks is not affiliated with or endorsed by any of the listed brokerages.
Live data via TradingView · NASDAQ:COSM
Chart provided by TradingView. Displayed for informational purposes only. No support levels, price targets, or technical predictions are shown or implied by TopStocks.
Receive emerging-company profiles, breaking market news, and time-sensitive stock alerts delivered to your inbox and your phone.
Free updates. Unsubscribe anytime. Educational and promotional content may be included.
Last Updated: Jun 11, 2026
Publisher: Relqo Media LLC (Wyoming, United States)
Subject Company: Cosmos Health Inc. (COSM)
This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Penzance LLC to produce and distribute promotional content regarding Cosmos Health Inc. (NASDAQ: COSM). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.
Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.
Relqo Media LLC has received cash compensation for the publication, distribution, and dissemination of investor awareness and promotional materials relating to Cosmos Health Inc. (NASDAQ: COSM).
Relqo Media LLC has received cash compensation in the amount of forty thousand dollars ($40,000) for promotional services to be rendered during a four-day campaign commencing on June 11, 2026 and concluding on June 15, 2026.
Relqo Media LLC has received cash compensation in the amount of forty thousand dollars ($40,000) for promotional services to be rendered during a four-day campaign commencing on May 31, 2026 and concluding on June 5, 2026.
Relqo Media LLC received cash compensation in the amount of twenty-five thousand dollars ($25,000) for promotional services rendered during a one-day campaign conducted on February 12, 2026.
Relqo Media LLC received cash compensation in the amount of twenty-seven thousand dollars ($27,000) for promotional services rendered during a short-term campaign conducted from February 3, 2026, through February 6, 2026.
Relqo Media LLC also received separate cash compensation in the amount of twenty thousand dollars ($20,000) for promotional services rendered in connection with a campaign conducted between November 24, 2025, and November 28, 2025.
Additionally,
These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.
Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.
Any and all information regarding Cosmos Health Inc. (NASDAQ: COSM)—including but not limited to business descriptions, operational updates, clinical trial progress, scientific data, partnerships, revenue projections, market opportunity estimates, or strategic plans—should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.
We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.
You should not rely on any company-provided claims, projections, or forward-looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.
If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence—including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts—before making any investment decision.
Historically, promotional campaigns for microcap and small-cap securities—particularly those driven by paid advertising—often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.
You should assume and expect that:
Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.
By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.
The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.
You are solely responsible for:
We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company’s business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.
By viewing our materials, you agree that:
Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as well as other predictive or aspirational language regarding future events, performance, or results. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “may,” “will,” “should,” “could,” “projects,” “estimates,” “potential,” and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to: changes in market conditions, regulatory decisions, the outcome of clinical trials, competitive pressures, the availability of financing, and broader economic or geopolitical developments.
Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated..
You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.
We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.
Assume all information presented by Relqo Media is:
Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including COSM. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.
We use a range of outreach and promotional tools, including:
By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.
Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.
We make good-faith efforts to disclose all:
We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.
This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.
All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:
Total liability for any claim shall not exceed one hundred dollars ($100).
All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.
Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.
We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.
If you do not accept all terms of this disclaimer in full, you must:
By viewing or engaging with this content, you agree that:
© 2024 Relqo Media LLC. All Rights Reserved.
Legal Contact: 📧 support@topstocks.com
Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801
Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.
